Introduction {#S1}
============

Differentiation-inducing factors 1-3 (DIFs 1-3) are chlorinated bioactive compounds identified in the slime mold *Dictyostelium discoideum,* which induce stalk cell differentiation \[[@R1],[@R2],[@R3]\]. Among them, DIF-1 is the most active in inducing stalk-cell differentiation, while DIF-2 has less activity than DIF-1. DIF-3, which is the first metabolite formed during DIF-1 degradation, has the lowest activity to induce stalk cells differentiation \[[@R3]-[@R5]\].

DIFs are considered anti-tumor agents because they inhibit proliferation of mammalian tumor cells *in vitro*, including leukemia \[[@R5]-[@R9]\], cervical \[[@R10]\], gastric \[[@R11]\], and colon \[[@R12]\] tumor cells. Activity of different DIFs to inhibit proliferation of mammalian tumor cells is converse to the activity demonstrated for differentiation of *D. discoideum* stalk cells; the most potent anti-tumor agent is DIF-3 \[[@R5],[@R7],[@R10]\]. Moreover, DIF-1and DIF-3 inhibit tumor growth in mice *in vivo* \[[@R12],[@R13]\].

Different intracellular pathways have been implicated in anti-proliferative effect of DIFs. Thus, DIF-3 reduces the expression of cyclin D1 mRNA by inhibiting Wnt/β- catenin signaling \[[@R12]\] and that DIF-1 and DIF-3 reduce protein level of cyclin D1 by accelerating its degradation via activation of GSK-3β \[[@R10],[@R12],[@R13]\]. In addition, DIF-1 inhibits proliferation of leukemia cells through inhibition of ERK and STAT3 signaling \[[@R8],[@R11]\]. It has also been shown that DIFs are direct inhibitors for PDE1 (calmodulin-dependent phosphodiesterase) \[[@R9]\].

Taken together, these findings shed a light on possible mechanisms of anti- proliferative effect of DIFs on tumor cells. However, the precise molecular machinery underlying the anti-proliferative action of DIFs remains to be elucidated.

PAK1 is a serine/ threonine kinase which regulates different intracellular functions including proliferation, cytoskeletal dynamics, cell survival, and gene transcription (reviewed in \[[@R14]\]). Altered expression and/or activation of PAK1 is evident in various cancers (reviewed in \[[@R15],[@R16]\]). The role for PAK1 in breast cancer has been studied to the most extent (reviewed in \[[@R14],[@R15]\]). The PAK1 gene amplifications are found in 17% of breast cancer \[[@R17],[@R18]\]. Over expression of PAK1 in human breast tumors correlates with tumor grade \[[@R19]-[@R22]\]. In a transgenic mouse model, PAK1 hyper activation leads to mammary gland tumors \[[@R23]\]. PAK1 plays a critical role in premalignant progression of MCF10 series of human breast epithelial cell lines \[[@R24]\]. PAK1 activation has been linked to ErbB2-dependent transformation of mammary epithelial cells \[[@R25],[@R26]\]. Recently, our lab has demonstrated a role for prolactin (PRL)- mediated tyrosyl phosphorylation of PAK1 in breast cancer cell motility, adhesion and invasion (reviewed in \[[@R27]\]). Thus, PAK1 has become one of the focal points in the investigation into the mechanism and onset of human breast cancer, and PAK1 inhibition represents plausible drug target in breast cancer.

In this study, to further corroborate the potential of DIFs as anti-proliferative agents, we investigate the effects of various DIF derivatives on PAK1 kinase activity. We show here that the different DIF derivatives inhibit PAK1 activity to varying degrees with the strongest inhibition in cells treated with DIF-3(+1) derivative. More importantly, it was found that the DIF-3(+1) directly inhibits PAK1 kinase activity *in vitro*. We also show here that DIF-3(+1) inhibits both cyclin D1 promoter activity and proliferation of MCF-7 and T47D breast cancer cells stably overexpressing PAK1. These results suggest that PAK1 is a direct target molecule of DIF-3(+1) which mediates the anti-proliferative effect of DIF-3(+1) on breast cancer cells.

Materials and Methods {#S2}
=====================

Cell cultures {#S3}
-------------

Parental and MCF-7 cells stably expressing HA-tagged PAK1 WT \[[@R28]\] were maintained in DMEM (Corning Cellgro) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich). Parental and T47D cells stably expressing myc-tagged PAK1 WT \[[@R29]\] were maintained in RPMI 1640 medium (Corning Cellgro) supplemented with 10% FBS.

Reagents and antibodies {#S4}
-----------------------

DIF derivatives ([Figure 1](#F1){ref-type="fig"}) were synthesized as described previously \[[@R5]\]. Human PRL was purchased from Dr. Parlow (National Hormone and Peptide Program NIDDK). Heregulin (HRG), epidermal growth factor (EGF) and estrogen (E2) were purchased from ProSci Inc, BD Biosciences and Sigma-Aldrich, respectively. Polyclonal αPAK (N- 20; Santa Cruz Biotechnology), and monoclonal αHA (Covance) antibodies were used in this study.

In vitro kinase assay {#S5}
---------------------

To assess PAK1 kinase activity, HA-PAK1 was immunoprecipitated with anti- HA antibody from cells treated with either vehicle, PRL (200 ng/ml, 20 min, E2 (1 nM, 30 min), or HRG (30 ng/ml, 15min) and DIF derivatives (20 μM for the indicated time) and subjected to an *in vitro* kinase assay in kinase buffer (50 mM HEPES, 100 mM NaCl, 5 mM MnCl2, 0.5 mM dithiothreitol, 1 mM Na~3~VO~4~; pH 7.6) in the presence of 10 μCi \[γ- ^32^P\] ATP (MP Biomedical), and 5 μg of histone H4 (substrate of PAK1; New England Biolabs) 10 μg/ml aprotinin, and 10 μg/ml leupeptin at 30°C for 30 min. Relative levels of incorporation of ^32^P into histone H4, an indicator of phosphorylation, were assessed by autoradiography and estimated by a phosphoimager screen. The same membrane was blotted with αHA to assess the amount of PAK1 for each condition. PVDF patterns were scanned and the amount of PAK1 was quantified using Multi-Analyst (Bio-Rad Laboratories) software. Relative PAK1 kinase activity was then normalized by the amount of immunoprecipitated PAK1 for each lane.

To assess direct inhibition of PAK1 by DIF-3(+1), GST- tagged PAK1 were purified using a glutathione-agarose affinity columns (Sigma-Aldrich). The purity of the proteins was monitored by SDS-PAGE. GST-tagged PAK1 was incubated with DIF- 3(+1) or THPH at 30°C for 30 min in kinase buffer containing 10 μCi of \[γ- ^32^P\] ATP, 10 μg/ml aprotinin, and 10 μg/ml leupeptin. Proteins were separated by SDS-PAGE and visualized by autoradiography followed by immunoblotting with indicated Ab.

Luciferase reporter gene assay {#S6}
------------------------------

Luciferase assay was performed as described previously \[[@R30]\]. MCF-7 cells stably over expressing PAK1 WT were co-transfected with cyclin D1-luciferase reporter and pCH110 plasmid containing a functional lacZ gene. The cells were serum deprived for 24 h, treated with either vehicle, 200 ng/ml of PRL, 1nM E2, 30 ng/ml HRG or 100 ng/ml EGF with or without 5 μM DIF-3(+1) for an additional 24 h. The cells were lysed, and luciferase activity was measured using Luciferase assay kit (Promega) according to the manufacturer's protocol. Luciferase values were corrected for transfection efficiency by determining the ratio of luciferase activity to β-galactosidase activity and expressed as "normalized cyclin D1-luciferase activity." Each transfection was performed in triplicate wells.

Cell proliferation assay {#S7}
------------------------

MCF-7 and T47D cells stably expressing PAK1 WT (5×10^3^ cells/well) were serum-deprived and allowed to grow for 7 days in 96-well plates. Each well contained 200 μl of DMEM (for MCF-7 clone) or RPMI (for T47D clone) were treated with either vehicle, 500 ng/ml of PRL, 1nM E2, 30 ng/ml HRG or 10 ng/ml EGF with or without 5 μM DIF-3(+1). In some experiments 5 μM IPA-3 (Tocris) was added. Cell proliferation was assessed by MTT cell proliferation assay (Life Technologies) according to manufacturer's protocol.

Statistical analysis {#S8}
--------------------

Data from at least three separate experiments per each condition were pooled and analyzed using one-way ANOVA plus Tukey's HSD test. Differences were considered to be statistically significant at P \< 0.05. Results are expressed as the mean ± standard error (S.E.).

Results and Discussion {#S9}
======================

DIF-3 and its derivatives inhibit PAK1 kinase activity in cells {#S10}
---------------------------------------------------------------

We have previously demonstrated that PRL-activated JAK2 tyrosine kinase phosphorylates and activates PAK1, resulting in the activation of cyclin D1 promoter activity and invasion of human breast cancer cells \[[@R30]-[@R32]\]. We thus assessed an effect of DIF-3 on PAK1 kinase activity because DIF-3 is the most potent anti-tumor agent among the original DIFs \[[@R5],[@R7],[@R10]\]. We treated MCF-7 cells stably expressing HA-PAK1 with DIF-3 over a time course followed by PRL treatment for 20 min. Immunoprecipitated PAK1 was assessed for PAK1 kinase activity by an *in vitro* kinase assay with histone H4 as a substrate. As expected, PRL increased PAK1 kinase activity by 2.6-fold, which was inhibited by DIF-3 in a time-dependent manner and reached the basal level by 2 h ([Figure 2A](#F2){ref-type="fig"}).

Next, we compared the inhibitory effect of some other DIF derivatives on PRL- dependent PAK1 kinase activity. The cells were incubated with the DIF derivatives (20 μM) for 2 h prior to PRL treatment. PAK1 kinase activity was inhibited by all the DIF derivatives to different degree with exception of DIF-2 and THPH ([Figure 2B](#F2){ref-type="fig"}). THPH is a non-bioactive analog of DIF-1 which affects neither cell growth nor cell differentiation \[[@R5]-[@R8]\]. Both DIF-1 and DIF-3 exhibit anti-proliferative activities in different human cancer cells, as was described in the Introduction section, and indeed both DIF-1 and -3 inhibit PAK1 activity. Meanwhile, DIF-2, which does not inhibit proliferation in human leukemia K562 cells \[[@R5]\], also does not inhibit PAK1 in our assay. We have demonstrated that DIF-3 inhibits PAK1 stronger than DIF-1 (63% inhibition by DIF-3 vs. 44% by DIF-1) ([Figure 2B](#F2){ref-type="fig"}). DIF-3 has been shown to exert a more powerful anti-proliferative effect than DIF-1 in human cervical cancer cells \[[@R10]\], leukemia \[[@R6],[@R8]\] and colon cancer cells \[[@R12]\]. Interestingly, the order of inhibitory effect of DIFs on PAK1 in MCF-7 cells described herein corresponds to the order of their potency to inhibit proliferation of human leukemia K563 cells: DIF-3 \> DIF-1 \> DIF-2 and THPH \[[@R7]\]. Since DIF-2 was ineffective in PAK1 kinase assay, hexanone (the alkyl group in DIF-1) rather than pentanone in DIF-2 \[[@R7]\] appeared to be important for inhibition of PAK1. Because chemically modified derivatives of DIF-3 (Bu-DIF-3) has been shown to be a more potent anti-proliferative agent than DIF-3 \[[@R5]\], we tested the effect of different derivatives of DIF-1 and DIF-3 on PAK1 activity and demonstrated that DIF-3 derivatives DIF-3(3M) and DIF-3(+1) inhibit PAK1 kinase activity to the maximal degree in MCF-7 cells (78% inhibition) ([Figure 2B](#F2){ref-type="fig"}).

Inhibition of PAK1 kinase activity by DIF-3(+1) is direct and ligand-independent {#S11}
--------------------------------------------------------------------------------

PAK1 is activated in response to PRL, estrogen and heregulin (a ligand for HER3 (human epidermal growth factor receptor-3) and HER4 (human epidermal growth factor receptor-4)) by different signaling pathways \[[@R32]-[@R34]\]. We decided to study whether the effect of DIF-3(+1), which has the strongest inhibitory effect of PAK1 activity, depends on a ligand. As demonstrated in [Fig. 3A](#F3){ref-type="fig"}, PAK1 kinase activity was inhibited by DIF-3(+1) to the basal level in response to all three PRL, E2 and HRG ([Figure 3A](#F3){ref-type="fig"}). These data suggests that DIF-3(+1) may act directly on PAK1 protein regardless of upstream effector.

To determine whether DIF-3(+1) directly inhibits PAK1, exogenous purified GST-PAK1 was combined with DIF-3(+1) or with biologically inactive THPH and the level of PAK1 autophosphorylation was assessed by the *in vitro* kinase assay as described above but in the absence of H4 substrate. Both concentrations of DIF-3(+1), 5 μM and 10 μM, inhibited PAK1 autophosphorylation to the same degree while THPH had no effect ([Figure 3B](#F3){ref-type="fig"}). These data suggest that DIF-3(+1) directly inhibits PAK1 *in vitro*.

DIF-3(+1) inhibits cyclin D1 promoter activity {#S12}
----------------------------------------------

Many factors, including PRL, E2, EGF, HRG, as well as activated PAK1 induce cyclin D1 expression (\[[@R35],[@R36]\]; reviewed in \[[@R37]\]) while DIF-1 and DIF-3 decrease cyclin D1 expression level by inducing cyclin D1 proteolysis via activation of GSK-3β \[[@R10],[@R12],[@R13]\]. We have previously showed that, in response to PRL, tyrosyl phosphorylated PAK1 activates cyclin D1 promoter activity \[[@R30]\]. Therefore, we sought to determine whether DIF-3(+1)-dependent inhibition of PAK1 kinase activity plays a role in cyclin D1 regulation in response to PRL, E2, EGF and HRG. First, we measured the induction of cyclin D1 promoter activity in MCF-7 PAK1 cells treated with or without PRL, E2, EGF and HRG. As shown in [Figure 4](#F4){ref-type="fig"}, the cells transfected with cyclin D1 promoter-luciferase construct demonstrated increased luciferase expression in response to PRL, E2, EGF and HRG as expected, with the greatest effect of HRG. However, when cells were treated with DIF-3(+1), induction of cyclin D1 promoter activity was significantly decreased for all four ligands studied ([Figure 4](#F4){ref-type="fig"}). These data suggest that DIF-3(+1) negatively regulates the activity of the cyclin D1 promoter. PAK1 has been previously implicated in induction of cyclin D1 expression \[[@R21],[@R36]\]. Balasenthil *et al.* proposed that active PAK1 can increase cyclin D1 transcription through two independent pathways-the NFκB pathway and phosphorylation of S305 of estrogen receptor alpha \[[@R21],[@R36]\]. We have previously demonstrated that, in response to PRL, tyrosyl phosphorylated PAK1 translocates into the nucleus to activate cyclin D1 promoter activity and that adapter protein Nck keeps PAK1 into the cytoplasm, preventing activation of cyclin D1 promoter activity \[[@R30]\]. As DIF-3 induces nuclear translocation of GSK-3β \[[@R10]\], we may speculate that DIF-3(+1) affects intracellular localization of PAK1 to retain PAK1 in the cytoplasm leading to inhibition of cyclin D1 expression.

DIF-3(+1) inhibits breast cancer cell proliferation {#S13}
---------------------------------------------------

DIFs exhibit powerful anti- proliferative effect in various cancer cells \[[@R5]-[@R12]\]. However, the effect of DIFs on breast cancer cells has not been studied. In this study, we examined whether DIF-3(+1) inhibits the proliferation of breast cancer cells. First, to confirm the role of PAK1 in cell proliferation, we treated MCF-7 PAK1 and T47D PAK1 cells with cell- permeable small-molecule PAK1 inhibitor IPA-3 \[[@R38],[@R39]\]. IPA-3 inhibited PRL- dependent proliferation of both MCF-7 and T47D cells ([Figure 5A](#F5){ref-type="fig"}). Next, as shown in [Figure 5B and C](#F5){ref-type="fig"}, PRL, E2, EGF and HRG induced proliferation of both MCF-7 and T47D cells to different degrees which probably depends on the amount of receptors to be activated by a ligand. We have shown that DIF-3(+1) strongly inhibited ligand-induced proliferation of both MCF-7 and T47D cells ([Figure 5B](#F5){ref-type="fig"} and [Figure 5C](#F5){ref-type="fig"}). Both cell lines were assessed for cytotoxicity for DIF-3(+1) which was not toxic (data not shown).

Conclusion {#S14}
==========

Based on our data presented here and previous studies, we suggest that DIF-1 and -3 inhibit PAK1 kinase in cells. We have found that DIF-3(+1) derivative inhibits PAK1 kinase activity both in cells and *in vitro* that leads to negative regulation of cyclin D1 promoter activity and inhibition of cell proliferation. We propose PAK1 as a DIF-3(+1) target which mediates the anti-proliferative effect of DIF-3(+1) on breast cancer cells.
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![Chemical structure of DIF derivatives.\
DIF derivatives were synthesized as described previously in Gokan et al. 2005 \[[@R5]\].](nihms-726981-f0001){#F1}

![DIF-3 and its derivatives inhibit PAK1 kinase activity in cells\
A) MCF-7 cells over expressing HA-tagged PAK1 were serum-deprived, pre-treated with or without 20 μM DIF-3 over a time course and stimulated with or without PRL (200 ng/ml, 20 min) to activate PAK1. HA-PAK1 was immunoprecipitated with anti-HA Ab, subjected to an *in vitro* kinase assay using H4 histone as a substrate and probed with anti- HA Ab. Relative PAK1 kinase activity was then normalized by the amount of PAK1 immunoprecipitated in each lane. The numbers at the bottom give the relative fold increase of ^32^P incorporation into H4 histone. The migrations of proteins are indicated.\
B) MCF-7 PAK1 cells were serum-deprived, pre-treated for 2 h with vehicle or 20 μM DIFs and their derivatives as indicated, followed by PRL treatment (200 ng/ml, 20 min). *In vitro* kinase assay was performed as described in A.](nihms-726981-f0002){#F2}

![DIF-3(+1) inactivates purified PAK1 *in vitro*\
A) MCF-7 PAK1 cells were serum-deprived, pre-treated with vehicle or 20 μM DIF-3 (+1) for 2 h, and stimulated with or without PRL (200 ng/ml, 20 min), E2 (1 nM, 30 min) or HRG (30 ng/ml, 15 min). Immunoprecipitated HA-PAK1 was subjected to the *in vitro* kinase assay as described in [Figure 2](#F2){ref-type="fig"}. Data are presented as in [Figure 2B](#F2){ref-type="fig"}). Purified GST- tagged PAK1 was subjected to *in vitro* kinase assay in the presence of DIF-3(+1) or THPH. The same membrane was probed with anti-PAK1 antibody for detection of GST-PAK1. Relative PAK1 kinase activity was then normalized by the amount PAK1 for each lane. The numbers at the bottom give the relative fold increase of ^32^P incorporation into PAK1.](nihms-726981-f0003){#F3}

![DIF-3(+1) decreases cyclin D1 promoter activity\
MCF-7 PAK1 cells were transfected with cyclin D1-luciferase reporter, serum-deprived and treated with vehicle or 5 μM DIF-3(+1) for 24 h in the presence of either vehicle, 200 ng/ml PRL, 1 nM E2, 10 ng/ml EGF or 30 ng/ml HRG. Luciferase activity was normalized with β-galactosidase activity. Bars represent mean ± S.E., \*, p \<0.05 compare with cells in the same condition treated with vehicle, n = 3.](nihms-726981-f0004){#F4}

![DIF-3(+1) inhibits breast cancer cell proliferation\
(A) MCF-7 and T47D cells overexpressing PAK1 were serum-deprived and incubated with vehicle (vcl), PRL (500 ng/ml) in presence or absence of IPA-3 (5μM). MCF-7 (B) or T47D (C) cells overexpressing PAK1 were serum-deprived and incubated with vehicle or 5 μM DIF-3(+1) in the presence of either vehicle, 500 ng/ml PRL, 1 nM E2, 10 ng/ml EGF or 30 ng/ml HRG. Cell density was assessed after seven days by MTT cell proliferation assay. Changes in cell numbers at day 7 are shown as percentages of the vehicle-treated cell number. Bars represent mean ± S.E., \*, p \<0.05 compare with cells in the same condition treated with vehicle, n = 3.](nihms-726981-f0005){#F5}
